Nonsteroidal anti-inflammatory drugs as a pharmacological alternative in Alzheimer's disease
DOI:
https://doi.org/10.33448/rsd-v12i10.43558Keywords:
Alzheimer's disease; Neurodegenerative; Pharmacotherapy; INEs.Abstract
Introduction: Inflammatory response in AD is characterized by the presence of activated microglia (the resident immunocompetent cells of the brain) in close association with neuritic plaques. Current evidence suggests that microglia are primarily involved in phagocytic activity and may be responsible for inducing additional neuronal damage by generating oxygen species and proteolytic enzymes. If anti-inflammatory drugs protect against the neurodegeneration seen in the brain of AD patients, then patients with a history of anti-inflammatory use should have a reduction in pathological changes in the brain and brain inflammation. Objective: to explain about the use of non-steroidal anti-inflammatory drugs as drug therapy for Alzheimer's disease. Results: Brain inflammation is believed to contribute to the pathological features of Alzheimer's disease (AD), and it has been postulated that anti-inflammatories protect against this tissue damage. However, one of the controversial factors regarding the use of non-steroidal anti-inflammatory drugs to reduce the risk of developing Alzheimer's disease is the toxicity associated with these drugs. Methodology: This is a systematic literature review with works searched in the following databases: National Library of Medicine (PubMed MEDLINE), Scientific Electronic Library Online (Scielo), Cochrane Database of Systematic Reviews (CDSR), Google Scholar, Library Health Virtual (VHL) and EBSCO Information Services. Relevant sources inherent to the theme were analyzed, using as one of the main criteria the choice of current, original and international articles. A total of 12 scientific articles were available for review. Final considerations: Anti-inflammatory drugs have been suggested as a possible treatment for Alzheimer's disease (AD). The association of immune proteins and immunocompetent microglial cells with senile plaques (SP) in AD and normal aging suggests that these drugs may be able to modify the course of AD, either interfering with SP formation or suppressing inflammation.
References
Aisen, P. S., et al. (2003). Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA, 289 (8), 2819-2826.
Brown, G. C., et al. (2003). Inflammatory neurodegeneration mediated by nitric oxide, glutamate and mitochondria. Mol Neurobiol., 27(3), 325-355.
Forlenza, O. V. (2005). Tratamento farmacológico da doença de Alzheimer. Rev Psiq Clin., 32 (3), 137-148.
Gyengesi, E., et al. (2020). In search of an anti-inflamatory drug for Alzheimer disease. News & Views, 16 (8), 131-133.
Hoozemans, J. J., et al. (2003). Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease. Curr Drug Targets., 4(6), 461-468.
Mackenzie, I. R. (2001). Postmortem studies of the effect of anti-inflammatory drugs on Alzheimertype pathology and associated inflammation. Neurobiol Aging, 22(6), 819-822.
McGeer, P. L., et al. (2006). Inflamação, agentes anti-inflamatórios e doença de Alzheimer: últimos 12 anos. IOS Press Content Library, 6 (8), 271-276.
Moore, A. H., et al. (2002). K. Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. Adv Drug Deliv Rev., 54(12), 1627-1656.
Parihar, M. S., et al. (2004). Alzheimer's disease pathogenesis and therapeutic interventions. J Clin Neurosci., 11(5), 456-467.
Reines, S. A., et al. (2004). Rofecoxib: no effect on Alzheimer´s disease in a 1-year, randomized, blinded, controlled study. Neurology, 62 (1), 66-671
Scali, C., et al. (2003). The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammatory and protects cholinergic neurons from excitotoxic degeneration in vivo. Neuroscience, 117(4), 909-919.
Sereniki, A., et al. (2008). A doença de Alzheimer: aspectos fisiopatológicos e farmacológicos. Rev Psiq RS, 30 (1), 1-17.
Tuppo, E. E., et al. (2005). The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol., 37(2), 289-305.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Flávia Demartine Borges de Oliveira; Larissa de Souza D’Angelo; Vinícius Bento Borges Oliveira; Anna Helena Pinheiro Araripe; Melissa Resende Oliveira; Louise Franchi Rigoldi; Angelina Crepaldi Camargo Lima; Isabela Garibaldi Cucolicchio; Bruna Capello Gervásio; Alice Maria Capello Gervásio
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
